List of Excipients in Branded Drug OFLOXACIN OPHTHALMIC

Generic Drugs Containing OFLOXACIN OPHTHALMIC

Company	Ingredient	NDC	Excipient
Altaire Pharmaceuticals Inc	ofloxacin	59390-140	HYDROCHLORIC ACID
Altaire Pharmaceuticals Inc	ofloxacin	59390-140	SODIUM CHLORIDE
Altaire Pharmaceuticals Inc	ofloxacin	59390-140	SODIUM HYDROXIDE
Altaire Pharmaceuticals Inc	ofloxacin	59390-140	WATER

What are the Most Frequently-Used Excipients in OFLOXACIN OPHTHALMIC?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
1	SODIUM CHLORIDE
1	SODIUM HYDROXIDE
1	WATER

Ofloxacin Ophthalmic Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Ofloxacin ophthalmic 0.3% is a mature, genericized fluoroquinolone product with limited opportunity for active-ingredient differentiation. The strongest commercial opportunities are in preservative-free delivery, multidose packaging, tolerability, pediatric usability, preservative compatibility, and supply-chain efficiency. The reference formulation uses benzalkonium chloride, sodium chloride, pH adjustment agents, and purified water, leaving room for excipient and container-closure innovation.[1]

What is the current formulation of ofloxacin ophthalmic?

Ofloxacin ophthalmic solution contains 0.3% ofloxacin, equivalent to 3 mg/mL. The reference product, Ocuflox, uses benzalkonium chloride as a preservative, sodium chloride for tonicity, hydrochloric acid and sodium hydroxide for pH adjustment, and purified water as the vehicle.[1]

Attribute	Reference-product profile
Active ingredient	Ofloxacin
Dosage form	Sterile ophthalmic solution
Strength	0.3%, or 3 mg/mL
Therapeutic class	Topical fluoroquinolone antibacterial
Preservative	Benzalkonium chloride
Tonicity agent	Sodium chloride
pH control	Hydrochloric acid and sodium hydroxide
Administration	Topical ocular instillation
Primary packaging	Sterile ophthalmic dropper container
Regulatory pathway for generics	ANDA, subject to applicable FDA requirements

Ofloxacin is a fluoroquinolone with activity against susceptible gram-negative and gram-positive ocular pathogens. The product is used for bacterial conjunctivitis and corneal ulcer indications under labeling that varies by market and product.[1]

The formulation is relatively simple from a chemical perspective. The principal technical risks are sterility, preservative effectiveness, container compatibility, pH stability, drop-size consistency, and patient tolerability.

What excipient functions are most important in ofloxacin eye drops?

The commercial formulation must balance four requirements: chemical stability, ocular comfort, microbiological protection, and consistent delivery.

Preservative system

Benzalkonium chloride, commonly abbreviated BAK, is used in the reference product at a low concentration. It provides antimicrobial protection in multidose packaging but can contribute to ocular-surface irritation, epithelial toxicity, tear-film disruption, and reduced tolerability with repeated use.[2]

This creates the clearest excipient opportunity. A developer can pursue:

• Preservative-free single-dose units
• Preservative-free multidose systems
• Alternative preservative systems
• Reduced-BAK formulations
• Packaging that prevents microbial ingress without conventional preservatives

A preservative-free formulation may be commercially attractive for patients with ocular-surface disease, recurrent treatment courses, contact-lens-related irritation, or sensitivity to BAK. The tradeoff is higher packaging cost, greater fill-finish complexity, and more demanding container-closure validation.

Tonicity adjustment

Sodium chloride adjusts osmotic pressure toward ocular tolerability. Alternative tonicity agents may include glycerol, boric acid, mannitol, or combinations of salts and polyols, but any substitution requires compatibility testing with ofloxacin, pH control, osmolality, and preservative performance.

The most commercially useful change is unlikely to be a novel tonicity agent by itself. Tonicity innovation has greater value when it supports a preservative-free, low-irritation, or multidose product.

Buffer and pH control

Ofloxacin ophthalmic products require controlled pH to maintain solubility, chemical stability, and comfort. Hydrochloric acid and sodium hydroxide are used for pH adjustment in the reference formulation.[1]

Potential development approaches include:

• Low-buffer-capacity systems that allow rapid normalization after instillation
• Citrate, phosphate, borate, or acetate buffer systems
• pH optimization for reduced stinging
• Buffer systems designed to preserve stability during temperature excursions
• Formulations with lower ionic strength for improved comfort

A buffer change can affect solubility, degradation, preservative activity, osmolality, and extractables from the package. It can therefore support a formulation patent only if the combination produces a measurable technical benefit.

Wetting and viscosity agents

Viscosity modifiers such as hydroxypropyl methylcellulose, hypromellose, povidone, polyethylene glycol, or hyaluronic acid may improve retention and reduce drainage. They can also increase residence time and potentially reduce dosing frequency.

The principal risks are:

• Blurred vision
• Increased drop size or dose variability
• Slower redispersion or filling problems
• Interaction with the container or dropper tip
• Altered antimicrobial activity
• More difficult sterile filtration
• Increased patient perception of residue

A modest viscosity increase may support a premium product, but the product must demonstrate a clear patient or dosing advantage over standard ofloxacin solution.

What preservative-free opportunities exist for ofloxacin ophthalmic?

Preservative-free ofloxacin is the most direct commercial opportunity in the excipient landscape.

Unit-dose preservative-free ofloxacin

Unit-dose packaging removes the need for a conventional antimicrobial preservative. The commercial advantages are ocular-surface tolerability and a simple safety narrative for short treatment courses.

The disadvantages are higher material use, more waste, increased packaging cost, and lower convenience for patients requiring treatment several times daily. Unit-dose products also require strong controls against sterility failures during filling and packaging.

A unit-dose product is most likely to compete in:

• Pediatric ophthalmology
• Postoperative care
• Patients with dry eye or ocular-surface disease
• Contact-lens-related treatment
• Hospital and ambulatory surgery settings
• Markets with strong demand for preservative-free eye drops

Preservative-free multidose packaging

A preservative-free multidose product is more technically difficult but has greater commercial differentiation. The container must limit microbial ingress through a one-way valve, filter, airless system, or equivalent design.

The intellectual-property value may reside in the packaging system rather than the excipient itself. Potentially protectable elements include:

• One-way fluid pathways
• Sterile vent filters
• Antimicrobial dropper-tip designs
• Airless pump mechanisms
• Metered-dose actuation
• Container geometry that prevents backflow
• Closure systems that maintain sterility after repeated use

The product must demonstrate container-closure integrity, dose uniformity, microbial ingress resistance, in-use stability, and compatibility with the formulation.

Which excipients could support a differentiated ofloxacin product?

Excipient or system	Potential benefit	Primary development risk	Commercial value
Hyaluronic acid	Longer retention, ocular comfort	Blurred vision, viscosity, sterility processing	Moderate to high
Hypromellose	Lubrication and retention	Drop-size variability, residue	Moderate
Povidone	Wetting and comfort	Compatibility and viscosity effects	Moderate
Glycerol or mannitol	Tonicity adjustment	Osmolality and stability changes	Low alone, higher in combination
Citrate or borate buffer	pH control	Preservative and solubility interactions	Moderate
Alternative preservative	Multidose protection with potential tolerability benefit	Efficacy, toxicity, regulatory acceptance	Moderate
Chelating agent	Enhanced preservative performance	Ocular tolerability and compatibility	Moderate
Antioxidant	Protection from oxidative degradation	Unnecessary excipient burden and safety review	Low unless degradation is demonstrated
Mucoadhesive polymer	Extended residence time	Blurring, manufacturability, patient acceptance	High if dosing reduction is achieved
Preservative-free package	Reduced ocular-surface exposure	Cost and sterility validation	High

Excipient selection should be driven by a specific product claim. "Improved comfort" requires comparative clinical or human-factors evidence. "Extended retention" requires pharmacokinetic or pharmacodynamic support. "Preservative-free" requires a package and in-use microbiological strategy that performs without BAK or another conventional preservative.

How does ofloxacin ophthalmic compare with competing fluoroquinolones?

Ofloxacin competes with ciprofloxacin, moxifloxacin, gatifloxacin where available, levofloxacin, and newer ophthalmic antibiotics. The competitive position depends on spectrum, dosing frequency, price, tolerability, formulation, and local resistance patterns.

Product category	Differentiation pressure on ofloxacin	Excipient opportunity
Ofloxacin 0.3% solution	Low price and established use	Preservative-free and comfort-focused products
Ciprofloxacin ophthalmic	Established generic competitor	Viscosity, suspension handling, and comfort differentiation
Moxifloxacin ophthalmic	Often positioned as a newer, convenient fluoroquinolone	Lower-cost preservative-free or premium-delivery alternative
Levofloxacin ophthalmic	Generic competition and established prescribing	Packaging and tolerability differentiation
Aminoglycoside or combination products	Different spectrum and use cases	Combination formulation and compatibility work
Non-antibiotic ocular products	Compete for shelf space and prescriber attention	Lubrication and ocular-surface positioning

Ofloxacin has limited scope for premium pricing based solely on the active ingredient. A differentiated product must offer a recognizable benefit such as preservative avoidance, improved comfort, fewer daily administrations, or easier administration.

What FDA regulatory status applies to ofloxacin ophthalmic?

Ofloxacin ophthalmic is an FDA-approved prescription ophthalmic antibacterial. Generic versions generally enter through the abbreviated new drug application pathway, which relies on pharmaceutical equivalence and bioequivalence or other applicable approval standards rather than a full new clinical efficacy program.[1,3]

A materially changed formulation may require additional regulatory work if the change affects:

• Active-ingredient release
• Ocular exposure
• Sterility assurance
• Preservative effectiveness
• Dosage form
• Dosing frequency
• Labeling claims
• Device performance
• Patient population

A standard solution with conventional excipients may fit a relatively familiar generic-development pathway. A preservative-free multidose product, viscous formulation, metered-dose device, or extended-retention product can require more extensive CMC, device, microbiology, human-factors, and clinical support.

FDA guidance on ophthalmic products emphasizes sterility, container-closure integrity, particulate control, extractables and leachables, stability, and microbiological quality.[3] USP standards relevant to development include ophthalmic preparations, sterility, particulate matter, and antimicrobial effectiveness testing where applicable.[4]

What patents protect ofloxacin ophthalmic products?

The ofloxacin active ingredient is a mature small molecule. Its original composition-of-matter and early pharmaceutical patents are expired or commercially obsolete in major markets. The main remaining patent opportunities are likely to involve formulation, delivery, packaging, manufacturing, or a specific method of use rather than the molecule itself.

Formulation patents

Potential claim categories include:

• Preservative-free aqueous ofloxacin solutions
• Specific pH and osmolality ranges
• Ofloxacin with a defined viscosity modifier
• Ofloxacin with a particular buffer and tonicity system
• Reduced-BAK formulations
• Stabilized formulations with defined degradation limits
• Combination products with lubricants or anti-inflammatory agents

A formulation patent is stronger when it ties a narrow composition to unexpected stability, improved tolerability, improved ocular residence time, or superior antimicrobial preservation.

Method-of-use patents

Potential method claims could address:

• Treatment of defined bacterial ocular infections
• Specific dosing regimens
• Pediatric treatment
• Contact-lens-associated infections
• Use in patients with ocular-surface disease
• Reduced-frequency dosing enabled by a retention-enhancing formulation

Method-of-use protection is difficult to monetize for a genericized antibiotic unless the indication or regimen is commercially meaningful and enforceable.

Manufacturing and process patents

Process protection may focus on:

• Sterile filtration and aseptic filling
• Control of particle formation
• Low-temperature processing
• Container sterilization
• In-line mixing and pH adjustment
• Improved batch-to-batch drop-size uniformity
• Reduced leachables or adsorption to the container

Manufacturing patents can provide operational value even when they do not support premium pricing. Their commercial role is strongest when they reduce batch failures, improve yield, or enable a package that competitors cannot easily reproduce.

When does ofloxacin ophthalmic lose exclusivity?

Ofloxacin ophthalmic has already lost market exclusivity as a conventional genericized product. There is no expected biosimilar pathway because ofloxacin is a chemically synthesized small molecule, not a biologic.

The relevant exclusivity analysis is therefore product-specific:

Exclusivity type	Status for conventional ofloxacin ophthalmic
Composition-of-matter exclusivity	Expired
New chemical entity exclusivity	Expired
Conventional generic entry	Established
Biosimilar exclusivity	Not applicable
Formulation exclusivity	Depends on any live, listed or unlisted patent
Device-related exclusivity	Depends on the package and regulatory structure
Pediatric exclusivity	Not expected to create a current market barrier
Market exclusivity for a new formulation	Possible only through a qualifying regulatory strategy

Any live patent assessment must distinguish patents listed in the FDA Orange Book from patents that may be enforceable but are not listed, including formulation, device, process, or method-of-use patents.[5]

What Orange Book status and Paragraph IV risks apply?

For a standard ofloxacin ophthalmic solution, Paragraph IV risk is generally lower than for a recently approved branded product because the active ingredient and conventional dosage form have been genericized for many years. The principal risk shifts to any patent covering a differentiated formulation, delivery device, or dosing regimen.

A generic applicant developing a new formulation should assess:

1. Orange Book-listed patents for the relevant reference product.
2. Patent families covering preservative-free or multidose delivery systems.
3. Continuation and divisional applications.
4. Patent term adjustment and terminal disclaimers.
5. Freedom-to-operate risks for container and valve mechanisms.
6. Method-of-use claims that could affect labeling.
7. Litigation history involving the reference product or its successor owner.

Paragraph IV exposure becomes more relevant where a new branded product combines ofloxacin with a proprietary delivery platform or claims a lower-frequency regimen. A conventional ANDA for a pharmaceutically equivalent solution usually faces a more predictable pathway than a 505(b)(2) product with altered residence time or dosing.

Which companies are positioned to commercialize differentiated ofloxacin ophthalmic products?

The market includes branded ophthalmic manufacturers, generic pharmaceutical companies, contract development and manufacturing organizations, and packaging suppliers. Competitive advantage is likely to come from formulation and device integration rather than API access.

Relevant commercial groups include:

• Generic ophthalmic manufacturers with sterile fill-finish capacity
• Branded ophthalmology companies with prescriber access
• Specialty pharmaceutical companies focused on preservative-free products
• Unit-dose packaging suppliers
• Airless and multidose ophthalmic-device developers
• CDMOs with ophthalmic aseptic manufacturing capability
• Regional companies serving markets where preservative-free products are underpenetrated

The strongest partnership model combines an established generic manufacturer with a proprietary packaging company. The manufacturer contributes regulatory and sterile manufacturing expertise; the packaging company contributes device IP, microbial-ingress data, and container-closure performance.

What commercial opportunities exist in ofloxacin ophthalmic?

Premium preservative-free product

A preservative-free product can command a premium if it demonstrates improved tolerability and earns formulary or prescriber adoption. The commercial case is strongest where patients use repeated courses or have pre-existing ocular-surface disease.

Pediatric and family-use packaging

Small, easy-to-administer unit doses, ergonomic bottles, tamper-evident closures, and clear dose indicators can improve usability. These features may support device patents and product-line differentiation.

Hospital and surgical channels

Hospitals and ambulatory surgery centers may value unit-dose sterile packaging, reduced contamination risk, and standardized administration. Procurement decisions will remain price-sensitive, so the product must show lower waste, lower contamination risk, or workflow value.

Emerging-market products

In price-sensitive markets, the opportunity may be a robust, low-cost formulation using readily available excipients and a reliable dropper system. Manufacturing localization, supply continuity, and packaging durability can matter more than premium excipients.

Combination and adjunctive products

A combination ofloxacin product with a lubricant or anti-inflammatory agent may create a new regulatory and patent profile. The development burden is higher because compatibility, clinical rationale, dosing, and labeling must be established. Antibiotic-steroid combinations also carry increased safety and regulatory complexity.

How strong is the patent estate for an ofloxacin ophthalmic reformulation?

The patent estate for the active ingredient is weak because ofloxacin is mature and genericized. A new product can build a moderate or strong estate only around a technically differentiated system.

Innovation type	Likely patent strength	Commercial defensibility
New excipient substituted for sodium chloride	Low	Low unless unexpected benefit is proven
New buffer range	Low to moderate	Moderate if linked to stability or comfort
Preservative-free unit dose	Moderate	Moderate, but design-around risk is high
Preservative-free multidose device	Moderate to strong	Stronger if device and formulation are integrated
Mucoadhesive extended-retention system	Moderate to strong	Potentially high if dosing frequency decreases
New manufacturing process	Moderate	Strong operational value, limited market exclusivity
New method of use	Low to moderate	Dependent on enforceability and prescription behavior
Combination product	Moderate	Higher regulatory burden and clinical risk

A defensible estate should use multiple claim layers: composition, concentration ranges, pH and osmolality, preservative system, container-device configuration, manufacturing process, and method of use. Overly broad excipient claims are vulnerable to invalidity or design-around arguments.

What generic launch risks exist for a differentiated ofloxacin product?

The main risks are regulatory classification, package performance, economics, and limited willingness to pay.

• A new excipient system may not materially improve outcomes.
• A preservative-free package may increase cost beyond the reimbursement premium.
• A viscosity modifier may cause blurred vision or inconsistent dosing.
• A multidose sterile system may fail microbial-ingress testing.
• A device patent may be designed around by changing the valve or container geometry.
• Fluoroquinolone resistance may reduce demand in some indications.
• Prescribers may substitute inexpensive conventional generics.
• Payers may not reimburse a premium for a mature antibiotic.
• Sterile manufacturing capacity can constrain launch timing.
• A 505(b)(2) strategy may require more clinical evidence than expected.

Key Takeaways

1. Ofloxacin ophthalmic 0.3% is a mature generic product with little active-ingredient exclusivity remaining.
2. The reference formulation uses BAK, sodium chloride, pH adjusters, and purified water.
3. Preservative-free delivery is the clearest excipient-led opportunity.
4. Preservative-free multidose packaging has greater commercial and patent potential than a simple excipient substitution.
5. Viscosity modifiers, lubricants, and mucoadhesive polymers can support premium positioning only if they improve retention, comfort, or dosing convenience.
6. The strongest IP estate would combine formulation claims with device, manufacturing, and method-of-use claims.
7. Biosimilar risk is not relevant because ofloxacin is a small-molecule antibiotic.
8. Commercial success will depend on reimbursement, sterile manufacturing economics, device reliability, and evidence of patient benefit.

FAQs

Can benzalkonium chloride be removed from ofloxacin ophthalmic?

Yes. A preservative-free formulation can use unit-dose packaging or a validated multidose container that limits microbial ingress. The reformulation must establish sterility, in-use microbiological performance, stability, and container compatibility.

Is hyaluronic acid compatible with ofloxacin ophthalmic?

Hyaluronic acid may be compatible, but compatibility cannot be assumed. The formulation must be evaluated for chemical stability, viscosity, sterility filtration, drop size, osmolality, preservative performance, and patient tolerability.

Can ofloxacin ophthalmic be reformulated for once-daily dosing?

A once-daily product would require evidence that the formulation sustains effective ocular exposure or otherwise supports reduced dosing. A simple excipient substitution would generally not establish once-daily performance.

Does ofloxacin ophthalmic have biosimilar competition?

No. Ofloxacin is a chemically synthesized small molecule. Competition occurs through generic drug applications and potentially through reformulated or device-enabled products.

What is the most defensible IP strategy for a new ofloxacin eye drop?

The strongest strategy is an integrated estate covering a specific formulation, preservative-free or reduced-preservative system, multidose container, manufacturing process, and clinically supported dosing or tolerability benefit.

References

1. U.S. Food and Drug Administration. (2017). Ocuflox (ofloxacin ophthalmic solution) 0.3% prescribing information. FDA.

2. U.S. Food and Drug Administration. (2013). Guidance for industry: Evaluation of drug products administered via ophthalmic, otic, and topical routes. FDA.

3. U.S. Food and Drug Administration. (2023). Quality considerations for ophthalmic drug products: Guidance for industry. FDA.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Ophthalmic preparations, sterility, particulate matter, and antimicrobial effectiveness testing. USP.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.